Firstly, the observed correlations between gut microbiota diversity and clinical parameters such as LoS, CRP, and NLR in COVID-19 patients with T2D suggest that monitoring gut microbiota diversity may serve as a non-invasive biomarker for disease severity and the response to treatment. This evidence concerns the gene CRP and COVID-19.